Figure 5.

Functional crosstalk of HGF-MET signaling pathway with EGFR and VEGFR signaling pathway.

Notes: The anticancer treatment with EGFR antibodies (cetuximab, panitumumab) or EGFR TKIs (gefitinib, erlotinib) leads to MET amplification with subsequent activation of PI3K-AKT signaling. The resistance can be prevented by dual inhibition of EGFR and MET. Similarly, MET-HGF signaling pathway activation help evade VEGFR inhibition induced by bevacizumab, sunitinib or pazopanib and dual inhibition with VEGFR and MET inhibitor might overcome the resistance to anticancer treatment.